In Vitro Induction of Human Dental Pulp Stem Cells to Lymphatic Endothelial Cells.

IF 1.2 4区医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cellular reprogramming Pub Date : 2022-05-13 DOI:10.1089/cell.2021.0106

Shuqun Qi, L. Ye, Liru Hu, Jian Pan

{"title":"In Vitro Induction of Human Dental Pulp Stem Cells to Lymphatic Endothelial Cells.","authors":"Shuqun Qi, L. Ye, Liru Hu, Jian Pan","doi":"10.1089/cell.2021.0106","DOIUrl":null,"url":null,"abstract":"Lymphedema is a progressive and irreversible disease due to the lymphatic system disorder. Conservative and surgical therapies are either ineffective or impractical. Currently, mesenchymal stem cells (MSCs)-based therapies seem to be the most promising treatment for lymphedema. The MSCs promote lymphangiogenesis through the paracrine approach or by directly differentiating into lymphatic endothelial cells (LECs) under the induction of growth factors. Human dental pulp stem cells (hDPSCs) have been suggested to play important roles in tissue regeneration, making it an attractive candidate for the lymphedema treatment. In this study, to evaluate the potential role of hDPSCs in the clinical application for lymphedema treatment, we induced the hDPSCs with vascular endothelial growth factor-C (VEGF-C) and investigated the lymphangiogenic differentiation potential of hDPSCs in vitro. We found that under the VEGF-C induction, hDPSCs demonstrated upregulated LECs specific markers, promoted cell proliferation and migration, and increased tube formation, all of which contributed to their differentiation into LECs in vitro.","PeriodicalId":9708,"journal":{"name":"Cellular reprogramming","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular reprogramming","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cell.2021.0106","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Lymphedema is a progressive and irreversible disease due to the lymphatic system disorder. Conservative and surgical therapies are either ineffective or impractical. Currently, mesenchymal stem cells (MSCs)-based therapies seem to be the most promising treatment for lymphedema. The MSCs promote lymphangiogenesis through the paracrine approach or by directly differentiating into lymphatic endothelial cells (LECs) under the induction of growth factors. Human dental pulp stem cells (hDPSCs) have been suggested to play important roles in tissue regeneration, making it an attractive candidate for the lymphedema treatment. In this study, to evaluate the potential role of hDPSCs in the clinical application for lymphedema treatment, we induced the hDPSCs with vascular endothelial growth factor-C (VEGF-C) and investigated the lymphangiogenic differentiation potential of hDPSCs in vitro. We found that under the VEGF-C induction, hDPSCs demonstrated upregulated LECs specific markers, promoted cell proliferation and migration, and increased tube formation, all of which contributed to their differentiation into LECs in vitro.

查看原文本刊更多论文

人牙髓干细胞体外诱导淋巴内皮细胞的研究。

淋巴水肿是由淋巴系统紊乱引起的一种进行性和不可逆的疾病。保守疗法和手术疗法要么无效，要么不切实际。目前，以间充质干细胞为基础的治疗方法似乎是治疗淋巴水肿最有前景的方法。MSCs通过旁分泌途径或在生长因子的诱导下直接分化为淋巴管内皮细胞（LECs）来促进淋巴管生成。人类牙髓干细胞（hDPSCs）已被认为在组织再生中发挥重要作用，使其成为治疗淋巴水肿的有吸引力的候选细胞。在本研究中，为了评估hDPSCs在淋巴水肿治疗的临床应用中的潜在作用，我们用血管内皮生长因子-C（VEGF-C）诱导hDPSCs，并在体外研究hDPSCs的淋巴管分化潜力。我们发现，在VEGF-C诱导下，hDPSCs表现出上调LECs特异性标记物，促进细胞增殖和迁移，并增加管的形成，所有这些都有助于它们在体外分化为LECs。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular reprogramming CELL & TISSUE ENGINEERING-BIOTECHNOLOGY & APPLIED MICROBIOLOGY

CiteScore

2.50

自引率

6.20%

发文量

审稿时长

3 months

期刊介绍： Cellular Reprogramming is the premier journal dedicated to providing new insights on the etiology, development, and potential treatment of various diseases through reprogramming cellular mechanisms. The Journal delivers information on cutting-edge techniques and the latest high-quality research and discoveries that are transforming biomedical research. Cellular Reprogramming coverage includes: Somatic cell nuclear transfer and reprogramming in early embryos Embryonic stem cells Nuclear transfer stem cells (stem cells derived from nuclear transfer embryos) Generation of induced pluripotent stem (iPS) cells and/or potential for cell-based therapies Epigenetics Adult stem cells and pluripotency.